

March 29, 2022

## Statewide Medicaid Managed Care (SMMC) Policy Transmittal: 2022-05

Applicable to the <b>2018-2023 SMMC contract benefits</b> for:	
	Managed Medical Assistance (MMA) and MMA Specialty
$\boxtimes$	Long-Term Care (LTC)
	Dental

Re: Community Pharmacy Dispensed Over the Counter (OTC) COVID-19 Home Tests

In accordance with the requirements of the <u>Families First Coronavirus Response Act</u> (FFCRA), Medicaid must cover COVID-19 tests intended for at-home testing (including tests where the individual performs self-collection of a specimen at home), when the test is ordered by an attending health care provider who has determined that the test is medically appropriate for the individual based on current accepted standards of medical practice and the test otherwise meets the statutory criteria in section 6001(a)(1) of the FFCRA. The purpose of this policy transmittal is to notify the managed care plan of Florida Medicaid's coverage of OTC COVID-19 home tests.

Coverage of Food and Drug Administration (FDA) authorized COVID-19 diagnostic and screening tests with at-home sample collection is effective January 4, 2022 under the requirements below.

## Eligible OTC COVID-19 Home Test Kits

Eligible OTC COVID-19 home test kits must have emergency use authorization or FDA approval for home use in both symptomatic and asymptomatic patients and allow for self-collection without medical observation. The eligible OTC COVID-19 home test kits covered by Florida Medicaid are those available in package sizes of one (1) or two (2) home tests only. The <a href="In Vitro Diagnostics EUAs-Antigen Diagnostic Tests for SARS-CoV-2">In Vitro Diagnostics EUAs-Antigen Diagnostic Tests for SARS-CoV-2</a> website lists all tests, however only those with "Home" as an Authorized Setting will be covered. This is the In Vitro Diagnostics EUAs-Antigen Diagnostic Tests for SARS-CoV-2 website: <a href="https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2#iaft1.">In Vitro Diagnostics-euas-antigen-diagnostic-tests-sars-cov-2#iaft1</a>.

## **Eliqible Enrollees**

Enrollees must have a prescription to obtain an eligible OTC COVID-19 home test kit.

## **Dispensing Providers**

Only community pharmacies are eligible to dispense the eligible OTC COVID-19 home test kits.

A maximum of four (4) eligible OTC COVID-19 home test kits per month per enrollee is covered; maximum unit overrides are available for medical necessity through the prior authorization process.



Statewide Medicaid Managed Care (SMMC) Policy Transmittal 2022-05 Re: Community Pharmacy Dispensed Over the Counter (OTC) COVID-19 Home Tests March 29, 2022 Page 2 of 2

- ❖ Pharmacies must bill for reimbursement using the National Drug Code (NDC) for the eligible OTC COVID-19 home test kits dispensed. Pharmacies will be reimbursed at a maximum rate of \$8.00 per unit (test kit), and an additional \$2.00 incentive payment per claim
- ❖ Pharmacists may prescribe and dispense the eligible OTC COVID-19 home test kits, as authorized by the Public Readiness and Emergency Preparedness (PREP) Act. Pharmacists that prescribe an eligible OTC COVID-19 home test kit must use their state license number in the "prescriber field" when billing for that eligible home test kit.

If you have questions, please contact your Agency contract manager at (850) 412-4004.

Sincerely,

Tom Wallace

Deputy Secretary for Medicaid

TW/sar